JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2004; 44:369-375, doi:10.1016/j.jacc.2004.03.069
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, C.
Right arrow Articles by Aukrust, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, C.
Right arrow Articles by Aukrust, P.

CLINICAL RESEARCH: ANTI-INFLAMMATORY THERAPY IN CORONARY ARTERY DISEASE

Potential anti-inflammatory role of activin A in acute coronary syndromes

Camilla Smith, MD*{dagger}, Arne Yndestad, MSc*, Bente Halvorsen, MSc, PhD*, Thor Ueland, BS*{ddagger}, Torgun Wæhre, MD*{dagger}, Kari Otterdal, MSc*, Hanne Scholz, MSc*, Knut Endresen, MD, PhD{dagger}, Lars Gullestad, MD, PhD||, Stig S. Frøland, MD, PhD*§, Jan Kristian Damås, MD, PhD*§ and Pål Aukrust, MD, PhD*§,*

* Research Institute for Internal Medicine, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
{dagger} Department of Cardiology, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
{ddagger} Section of Endocrinology, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
§ Section of Clinical Immunology and Infectious Diseases, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
|| Department of Medicine, Bærum Hospital, Sandvika, Norway

Manuscript received December 16, 2003; revised manuscript received March 23, 2004, accepted April 3, 2004.

* Reprint requests and correspondence: Dr. Pål Aukrust, Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshopitalet, Sognsvannsveien 20, 0027 Oslo, Norway.
pal.aukrust{at}rikshospitalet.no

OBJECTIVES: We sought to investigate whether activin A could be involved in the immunopathogenesis of acute coronary syndromes.

BACKGROUND: Inflammatory mechanisms seem to play a pathogenic role in atherosclerosis and acute coronary syndromes, but the actual mediators have not been fully identified. Activin A, a pleiotropic member of the transforming growth factor-beta cytokine family, has recently been suggested to play a role in inflammation.

METHODS: We examined the role of activin A and its endogenous inhibitor follistatin in patients with stable (n = 26) and unstable angina (n = 20) and healthy control subjects (n = 20) by different experimental approaches.

RESULTS: 1) Patients with stable angina had raised activin A concentrations, as assessed by protein levels in serum and messenger ribonucleic acid levels in peripheral blood mononuclear cells (PBMCs). 2) Although several activin A–related mediators were upregulated in PBMCs from patients with stable angina compared with controls (i.e., activin A and Smad3), no changes or even downregulation (i.e., Smad2) were seen in unstable disease. 3) The activin type II receptors, representing the primary ligand-binding proteins, were downregulated in unstable compared with stable angina. 4) Percutaneous coronary intervention induced a decrease in the activin A/follistatin ratio, suggesting downregulatory effects on activin A activity. 5) Although activin A dose-dependently suppressed the release of inflammatory cytokines from PBMCs in angina patients, an opposite effect was found in healthy controls.

CONCLUSIONS: Our findings suggest an anti-inflammatory potential of activin A in angina patients, and such effects may be of particular relevance in unstable angina in which several of the activin parameters were downregulated.

Abbreviations and Acronyms
  CAD = coronary artery disease
  EIA = enzyme immunoassay
  IL = interleukin
  MIP = macrophage inflammatory protein
  mRNA = messenger ribonucleic acid
  PBMC = peripheral blood mononuclear cell
  PCI = percutaneous coronary intervention
  TGF = transforming growth factor
  TNF = tumor necrosis factor




This article has been cited by other articles:


Home page
CirculationHome page
H. Scholz, W. Sandberg, J. K. Damas, C. Smith, A. K. Andreassen, L. Gullestad, S. S. Froland, A. Yndestad, P. Aukrust, and B. Halvorsen
Enhanced Plasma Levels of LIGHT in Unstable Angina: Possible Pathogenic Role in Foam Cell Formation and Thrombosis
Circulation, October 4, 2005; 112(14): 2121 - 2129.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.